DocuSign Envelope ID: 1060F395-21EA-480D-9F98-154F538D5920
PFIC ANNUAL INFORMATION STATEMENT | |
Name of PFIC: | Molecular Partners AG |
PFIC Address: | Wagistrasse 14,8952 Schlieren |
Zurich SZ | |
PFIC EIN, if applicable: | 98-1030360 |
PFIC Country of Organization: | Switzerland |
Molecular Partners AG may be considered a Passive Foreign Investment Company ("PFIC") for U.S. federal income tax purposes. The following information is provided to allow a shareholder of Molecular Partners AG to make an election under Section 1295 of the Internal Revenue Code to treat Molecular Partners AG as a Qualified Electing Fund ("QEF") for U.S. federal income tax purposes. The PFIC rule are complex. Please consult your tax advisor.
As an interest holder in Molecular Partners AG, a foreign corporation for U.S. federal income tax purposes, the following information is hereby being provided to you in accordance with Treasury Regulations Section 1.1295-1(g)(1).
- This PFIC Annual Information Statement applies to the taxable year of Molecular Partners AG beginning January 1, 2023 and ending December 31, 2023.
- The shareholder's per share, per day information of the ordinary earnings and net capital gain (as defined in Treasury Regulations Sections 1.1293-1(a)(2)) of Molecular Partners AG for the taxable year specified in paragraph (1) were:
Ordinary Earnings: | USD 0.000000 |
Long term Capital Gain: | USD 0.000000 |
- The amount of cash and fair market value of other property distributed or deemed distributed by Molecular Partners AG during the taxable year specified in paragraph (1) is as follows:
Cash:NONE
Property:NONE
- Molecular Partners AG will permit its shareholders to inspect and copy its permanent books of account, records, and such other documents as may be maintained by Molecular Partners AG to establish that Molecular Partners AG's ordinary earnings and net capital gain are computed in accordance with U.S. income tax principles, and to verify these amounts and its shareholder's pro rata shares thereof.
_____________________________________________________________
Robert Hendriks
SVP Finance (Principal Accounting Officer)
April 2, 2024
_____________________________________________________________
Date
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Molecular Partners AG published this content on 18 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 April 2024 13:28:09 UTC.